skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Combination therapy or monotherapy for the depressed type of schizoaffective disorder

Original Research

(3662) Views  (797) Full article downloads

Authors: Lubomira Izáková, Ivan Andre, Angelos Halaris

Published Date February 2009 Volume 2009:5 Pages 91 - 101
DOI: http://dx.doi.org/10.2147/NDT.S4271

Lubomira Izáková1, Ivan Andre1, Angelos Halaris2

1Psychiatric Clinic, Faculty of Medicine Comenius University and Faculty Hospital, Bratislava, Slovakia; 2Department of Psychiatry and Behavioral Neurosciences, Loyola University Medical Center, Maywood, IL, USA

Abstract: Several studies have demonstrated the effectiveness of adjunctive antidepressant drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, however, monotherapy with atypical antipsychotics may be advantageous. We compared the efficacy and safety of risperidone monotherapy versus combination therapy of haloperidol with sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: risperidone: 3.75–3.29 mg/day, haloperidol: 5.35–4.15 mg/day, sertraline: 65.39–133.82 mg/day. Efficacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperidone patients showed statistically significant greater improvement than haloperidol-sertraline patients on efficacy measures including Positive and Negative Syndrome Scale and Clinical Global Impressions rating. A higher number of risperidone patients dropped out of the study early. Fewer adverse events and lesser need for concomitant medications occurred in patients on risperidone. The risperidone group showed better psychological, social and occupational functioning (Global Assessment of Functioning) and higher quality of life (Heinrich’s Quality of Life Scale). Risperidone has higher antipsychotic efficacy and tolerability compared with haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed type. Both treatments were comparable in terms of antidepressant efficacy.

Keywords: schizoaffective disorder, depressed type, risperidone, haloperidol, sertraline








Readers of this article also read:

Psychopharmacology of ADHD in pediatrics: current advances and issues
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pregabalin for the management of fibromyalgia syndrome
Enucleation following treatment with intravenous pentamidine for Acanthamoeba sclerokeratitis
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Romidepsin in the treatment of cutaneous T-cell lymphoma
Erratum
Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use
Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia